argenx (ARGX) Stock Forecast & Price Target

Argenx has demonstrated significant revenue growth, achieving $790 million in Q1 2025 and $949 million in Q2 2025, reflecting a 97% year-over-year increase and driven by the expanding use of Vyvgart in both generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP). The company's innovative subcutaneous formulation, Vyvgart Hytrulo, has broadened the prescriber base, with approximately 1,000 prescribers adopting the pre-filled syringe format, suggesting strong market penetration and potential for sustained growth. Looking ahead, argenx anticipates further expansion through label extensions for various indications, increased uptake in earlier lines of therapy, and promising clinical data from ongoing studies, all of which contribute to a favorable outlook for the company's stock.

Argenx faces several fundamental risks that contribute to a negative outlook on its stock, including the potential for lower-than-anticipated growth in Vyvgart sales and the possibility of unforeseen safety signals emerging in ongoing clinical trials for efgartigimod and empasiprubart. Additionally, the company may confront increased competition within the biopharmaceutical space, particularly as macroeconomic challenges such as inflation and foreign exchange fluctuations could impact its operational costs and overall performance. Furthermore, setbacks in research and development, regulatory approvals, or commercial initiatives could adversely affect Argenx's growth trajectory, creating further uncertainty for investors.